These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17627931)

  • 1. Hemoglobin variability in dialysis patients.
    Brimble KS; Clase CM
    J Am Soc Nephrol; 2007 Aug; 18(8):2218-20. PubMed ID: 17627931
    [No Abstract]   [Full Text] [Related]  

  • 2. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaemia management in non-dialysis chronic kidney disease: flexibility of target to target stability?
    De Nicola L; Minutolo R; Conte G
    Nephron Clin Pract; 2010; 114(4):c236-41. PubMed ID: 20090364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin levels, quality of life, and survival.
    Sadler JH; Meyer KB
    Nephrol News Issues; 2007 Aug; 21(9):42-3. PubMed ID: 17722853
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 7. [Role of renal anemia in progression of chronic kidney disease].
    Racki S; Maleta I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 9. [How to optimize the concept of the variability of haemoglobin in dialysis patients].
    Kessler M
    Nephrol Ther; 2008 Dec; 4(7):547-8. PubMed ID: 18809370
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of erythropoietin stimulating agent (ESA) automated adjustment protocols on hemoglobin levels and mortality in end stage renal disease patients.
    Kolankiewicz LM; Weinberg DA; Rothstein M; Weinberg MS
    Med Health R I; 2012 Jun; 95(6):172-5. PubMed ID: 22866503
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hemoglobin variability in patients with chronic renal insuffiency].
    Deray G
    Nephrol Ther; 2008 Dec; 4(7):549-52. PubMed ID: 19004677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin bubble: a severe German case Honi soit qui mal y pense.
    Wizemann V
    Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of anemia in patients with chronic renal disease: is it time for self-criticism?].
    Del Vecchio L
    G Ital Nefrol; 2007; 24(4):285. PubMed ID: 17659497
    [No Abstract]   [Full Text] [Related]  

  • 17. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
    Fishbane S; Jhaveri KD
    Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 19. A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin.
    Koncicki HM; Fishbane S
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1173-1175. PubMed ID: 28522653
    [No Abstract]   [Full Text] [Related]  

  • 20. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices.
    Pisoni RL; Bragg-Gresham JL; Fuller DS; Morgenstern H; Canaud B; Locatelli F; Li Y; Gillespie B; Wolfe RA; Port FK; Robinson BM
    Am J Kidney Dis; 2011 Feb; 57(2):266-75. PubMed ID: 21251541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.